← Back to Patent Explorer
US5219740A Expired / Lapsed US ⏱️ 0.0 years remaining

Retroviral gene transfer into diploid fibroblasts for gene therapy

Assignee: Fred Hutchinson Cancer Center
•
Filing: 1987-02-13
•
Granted: 1993-06-15
•
Expires: 2007-02-13
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A process of mammalian gene therapy. Explanted fibroblasts are genetically modified by introducing a retroviral construct containing a nucleotide sequence encoding for a therapeutic substance. The genetically modified fibroblasts are implanted into a mammalian subject.

Inventors

  • 👤 A. Dusty Miller
  • 👤 Theo D. Palmer

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 11:28
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/85; C12N15/86; A; A61; A61K; A61K48/00; A61K49/00; C12N2740/00; C12N2740/00011; C12N2740/10011; C12N2740/13011; C12N2740/13041; C12N2740/13043

Claims Analysis

Total Claims: 8
Claim 1
Independent Claim 139 words
A process of gene transfer into diploid fibroblasts in vitro, comprising the step of: genetically modifying diploid fibroblasts explanted from a mammalian subject by a process consisting essentially of introducing into said fibroblasts a retroviral construct comprising a first nucleotide sequence encoding a first expression product, a viral long terminal repeat and a promoter sequence upstream of said first nucleotide sequence, and a viral long terminal repeat and a polyadenylation sequence downstream of said first nucleotide sequence, wherein said retroviral construct lacks one or more of the gag, pol, and env sequences required for retroviral replication, by contacting said fibroblasts with said retroviral construct in a virus-containing medium having a viral titer of at least about 10 5 cfu/ml on NIH 3T3 fibroblasts to produce a population of fibroblasts at least 1% of which express said first expression product.
Claim 2
Dependent Claim 139 words
A process of gene transfer into diploid fibroblasts in vitro, comprising the step of: genetically modifying diploid fibroblasts explanted from a mammalian subject by a process consisting essentially of introducing into said fibroblasts a retroviral construct comprising a first nucleotide sequence encoding a first expression product, a viral long terminal repeat and a promoter sequence upstream of said first nucleotide sequence, and a viral long terminal repeat and a polyadenylation sequence downstream of said first nucleotide sequence, wherein said retroviral construct lacks one or more of the gag, pol, and env sequences required for retroviral replication, by contacting said fibroblasts with said retroviral construct in a virus-containing medium having a viral titer of at least about 10 5 cfu/ml on NIH 3T3 fibroblasts to produce a population of fibroblasts at least 1% of which express said first expression product.
Claim 3
Dependent Claim 38 words
The process of claim 1, wherein said retroviral construct further comprises a second nucleotide sequence encoding a second expression product, and wherein one of the first and the second expression products confers resistance to a selectable marker substance.
Claim 4
Dependent Claim 20 words
The process of claim 2, wherein said selectable marker substance is selected from the group consisting of G418 and Hygromycin-B.
Claim 5
Dependent Claim 18 words
The process of claim 1, wherein said diploid fibroblasts are explanted from the tissue of a mammalian subject.
Claim 6
Dependent Claim 12 words
The process of claim 1, wherein said mammalian subject is a human.
Claim 7
Dependent Claim 28 words
The process of claim 2, wherein the other of the first and the second expression products is selected from the group consisting of enzymes, hormones, and precursors thereof.
Claim 8
Dependent Claim 32 words
The process of claim 6, wherein the other of the first and the second expression products is selected from the group consisting of adenosine deaminase, purine nucleoside phosphorylase, and blood clotting factors.

References Cited (Backward Citations)

US4396601A Cited
US4497796A Cited
US4485096A Cited
US4686098A Cited
WO1987000201A1 Cited
US4868116A Cited
US4861719A Cited
WO1989002468A1 Cited
WO1989007136A2 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1996-06-14 1996-12-14 1997-06-15 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2000-06-14 2000-12-14 2001-06-15 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2004-06-14 2004-12-14 2005-06-15 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag